Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 11/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517549 | 0.87 | HTR4 (0.42) | DRD2DRD3 | |
| SCHEMBL24207313 | 0.86 | DRD2 (0.45) | SUV39H2DRD2 | |
| SCHEMBL518051 | 0.83 | LMNA (0.43) | SUV39H2CKS1BSKP1SKP2DRD2 | |
| SCHEMBL29435443 | 0.82 | SUV39H2 (0.53) | SUV39H2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL517615 | 0.82 | SUV39H2 (0.53) | SUV39H2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL22246109 | 0.81 | GAA (0.49) | CKS1BSKP1SKP2DRD2DRD3 | |
| SCHEMBL20149913 | 0.80 | SUV39H2 (0.48) | SUV39H2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL26484666 | 0.80 | SUV39H2 (0.50) | SUV39H2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL4435954 | 0.79 | ALDH1A1 (0.47) | SUV39H2CKS1BSKP1SKP2DRD2 | |
| SCHEMBL4443945 | 0.78 | CKS1B (0.47) | CKS1BSKP1SKP2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | SUV39H2 2407/4885CFTR 1516/4885CKS1B 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.